1 month ago
16 ARTICLE AD
While artificial intelligence (AI) promises to transform all manner of industries, the biggest game-changing breakthroughs in this new era of data-infused machine intelligence arguably lies in the field of drug discovery. By analyzing vast amounts of biological data, AI can help researchers predict how different chemical compounds will interact with specific targets in the body, accelerating the discovery of promising drug candidates.
It’s against this backdrop that Cambridge University spinout CardiaTec is striving to tackle cardiovascular diseases (CVD). To bolster its efforts, the company today said it has raised $6.5 million in a seed round of funding.
CVDs are the preeminent cause of death globally, resulting in 17.9 million deaths each year, according to The World Health Organization (WHO). At the top of the list is ischaemic heart disease (coronary heart disease), responsible for 13% of the world’s total deaths.
Founded in 2021, CardiaTec is the handiwork of biotech and bioengineering graduates Raphael Peralta (CEO) and Thelma Zablocki (COO). They’re supported by their third co-founder and CTO, Namshik Han, a lecturer in AI drug discovery at the University of Cambridge, where Peralta and Zablocki studied for an MPhil in Bioscience Enterprise. Han, who has a background in machine learning, computational biology, cancer genomics, and cancer epigenomics, is also head of AI at the university’s Milner Therapeutics Institute, which forges close ties with industry, including pharmaceutical companies.
“He (Han) is an academic who sits on the border with industry, so he understands that translational perspective,” Peralta told TechCrunch in an interview. “We came together with the opportunity to use Namshik’s work, but within the cardiovascular space.”
CardiaTec is tackling the crux of the problem: The average expense of progressing a drug candidate from discovery through launch is around $2.2 billion, and that cost is driven substantively by the fact that 90% of potential candidates fail in the process, according to Deloitte. CardiaTec is setting out to “decode” the biology of CVDs.
To do this, the company has struck partnerships with 65 hospitals across the U.K. and the U.S., which are providing human heart tissue as part of the company’s broader data collection efforts, which will help it build what it calls the “largest human heart tissue-multi-omics dataset,” spanning a broad gamut of biological information from across molecular biology. By doing this, CardiaTec hopes to identify novel, targeted therapeutics.
“Historically, it’s been very difficult to access human tissue, especially those of deceased people because of matters related to consent, ethics, and logistics,” Peralta said. “Now the infrastructure in hospitals is much more embedded, and we can actually begin to get access to these human tissues and generate data.”
In the context of cardiovascular disease, this means that CardiaTec can compare healthy artery tissue with that of an artery where plaque buildup has led to a heart attack, and generate the data its computational models need further downstream. Such computational approaches, involving a vast amount of different “multi-omics” data types, are capable of aggregating and analyzing data at a scale humans simply can’t match.
“We can now look not just in genetics, but we can look at genetics, epigenetics, gene expression, protein function, all in a single model,” Peralta said. “So we have a much more in depth understanding of the mechanisms that are driving disease.”
CardiaTec co-founder and CEO Raphael PeraltaImage Credits: CardiaTec (opens in a new window)
Heart of the problem
While drugs made with help from AI have yet to make it to market, the early promise has created a wave of excitement and a swathe of startups have raised bucketloads of cash in the process. In the past few months alone, we’ve seen the likes of Xaira emerge from stealth with $1 billion in funding, while Sam Altman-backed Formation Bio raised $372 million. In the U.K., meanwhile, Healx has nabbed $47 million to identify new drugs for rare diseases.
Heavily VC-backed pharmaceutical startup Insilico Medicine recently claimed a world’s first when it announced that it had identified a new drug candidate for a rare lung disease called idiopathic pulmonary fibrosis. AI played a pivotal role not only in designing the drug’s chemical structure, but in figuring out which part of a cell it should be targeting. The drug was initially tested in animals, and is currently in “Phase II” trials in the U.S. and China, where it’s hoped it will generate the evidence needed to establish its efficacy in treating humans.
Elsewhere, AI is being used to help discover everything from new antibiotics for tackling superbugs, to drugs for treating obsessive compulsive order (OCD).
Citing data from peer-reviewed journal Nature Reviews Drug Discovery, Peralta said one of CardiaTec’s main differentiators is that its focus lies squarely on cardiovascular disease, which only 3% of active AI-first companies are targeting.
“The majority of companies who are applying AI in therapeutic discovery are in oncology, followed by central nervous systems and neurogenic diseases, respiratory and infectious diseases, and then way at the bottom of the list is cardiovascular diseases,” Peralta said. “Cardiovascular disease is the world’s leading global cause of death — not a lot of people know that, but there’s a big unmet need that hasn’t been captured in pharma.”
CardiaTec had previously raised $1.8 million in pre-seed funding, and with this fresh $6.5 million in cash, the company is well-financed to extend its proprietary data gathering efforts, wet lab validation of its therapeutic targets model, and bolster its eight-person team in Cambridge. The next step is to start identifying and testing actual drug candidates, which — in the grand scheme of drug R&D — is likely to be several years away.
CardiaTec’s seed round was led by Montage Ventures, with participation from Continuum Health Ventures, Laidlaw Ventures, Apex Ventures, and a number of angel investors.
